PubMed:33152450 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":853,"end":856},"obj":"Body_part"},{"id":"T2","span":{"begin":1068,"end":1071},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.\nBACKGROUND: There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19).\nMETHODS: Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes.\nRESULTS: The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]: 8.4-12.8) for AP group and 19.3±2.1 days (95% CI: 15.1-23.5) for the control group. The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. The CT imaging within ten days post-treatment showed no significant differences between the two groups (p\u003e0.05). Both groups had mild adverse events.\nCONCLUSIONS: In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. However, physicians should consider the QT interval changes before using AP."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":64,"end":72},"obj":"Disease"},{"id":"T2","span":{"begin":190,"end":214},"obj":"Disease"},{"id":"T3","span":{"begin":216,"end":224},"obj":"Disease"},{"id":"T4","span":{"begin":270,"end":278},"obj":"Disease"},{"id":"T5","span":{"begin":474,"end":521},"obj":"Disease"},{"id":"T6","span":{"begin":474,"end":507},"obj":"Disease"},{"id":"T7","span":{"begin":523,"end":531},"obj":"Disease"},{"id":"T8","span":{"begin":588,"end":596},"obj":"Disease"},{"id":"T9","span":{"begin":1447,"end":1455},"obj":"Disease"},{"id":"T10","span":{"begin":1488,"end":1496},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.\nBACKGROUND: There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19).\nMETHODS: Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes.\nRESULTS: The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]: 8.4-12.8) for AP group and 19.3±2.1 days (95% CI: 15.1-23.5) for the control group. The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. The CT imaging within ten days post-treatment showed no significant differences between the two groups (p\u003e0.05). Both groups had mild adverse events.\nCONCLUSIONS: In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. However, physicians should consider the QT interval changes before using AP."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":82,"end":87},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T2","span":{"begin":360,"end":362},"obj":"http://purl.obolibrary.org/obo/CLO_0001547"},{"id":"T3","span":{"begin":396,"end":400},"obj":"http://purl.obolibrary.org/obo/CLO_0007919"},{"id":"T4","span":{"begin":396,"end":400},"obj":"http://purl.obolibrary.org/obo/CLO_0007920"},{"id":"T5","span":{"begin":677,"end":680},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T6","span":{"begin":947,"end":949},"obj":"http://purl.obolibrary.org/obo/CLO_0001547"},{"id":"T7","span":{"begin":1164,"end":1166},"obj":"http://purl.obolibrary.org/obo/CLO_0001547"},{"id":"T8","span":{"begin":1272,"end":1275},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T9","span":{"begin":1532,"end":1534},"obj":"http://purl.obolibrary.org/obo/CLO_0001547"},{"id":"T10","span":{"begin":1646,"end":1648},"obj":"http://purl.obolibrary.org/obo/CLO_0001547"}],"text":"Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.\nBACKGROUND: There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19).\nMETHODS: Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes.\nRESULTS: The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]: 8.4-12.8) for AP group and 19.3±2.1 days (95% CI: 15.1-23.5) for the control group. The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. The CT imaging within ten days post-treatment showed no significant differences between the two groups (p\u003e0.05). Both groups had mild adverse events.\nCONCLUSIONS: In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. However, physicians should consider the QT interval changes before using AP."}

LitCovid-PD-CHEBI

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":23,"end":46},"obj":"Chemical"},{"id":"3","span":{"begin":64,"end":72},"obj":"Disease"},{"id":"18","span":{"begin":176,"end":184},"obj":"Species"},{"id":"19","span":{"begin":190,"end":214},"obj":"Disease"},{"id":"20","span":{"begin":216,"end":224},"obj":"Disease"},{"id":"21","span":{"begin":246,"end":254},"obj":"Species"},{"id":"22","span":{"begin":270,"end":278},"obj":"Disease"},{"id":"23","span":{"begin":335,"end":358},"obj":"Chemical"},{"id":"24","span":{"begin":474,"end":521},"obj":"Species"},{"id":"25","span":{"begin":523,"end":533},"obj":"Species"},{"id":"26","span":{"begin":557,"end":569},"obj":"Species"},{"id":"27","span":{"begin":588,"end":598},"obj":"Species"},{"id":"28","span":{"begin":1035,"end":1043},"obj":"Species"},{"id":"29","span":{"begin":1416,"end":1424},"obj":"Species"},{"id":"30","span":{"begin":1447,"end":1455},"obj":"Disease"},{"id":"31","span":{"begin":1488,"end":1498},"obj":"Species"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Tax:9606"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:C000657245"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:C000657245"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:9606"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"MESH:C000657245"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:2697049"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:2697049"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:9606"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Tax:2697049"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Tax:9606"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Tax:9606"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.\nBACKGROUND: There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19).\nMETHODS: Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes.\nRESULTS: The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]: 8.4-12.8) for AP group and 19.3±2.1 days (95% CI: 15.1-23.5) for the control group. The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. The CT imaging within ten days post-treatment showed no significant differences between the two groups (p\u003e0.05). Both groups had mild adverse events.\nCONCLUSIONS: In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. However, physicians should consider the QT interval changes before using AP."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":126},"obj":"Sentence"},{"id":"T2","span":{"begin":127,"end":138},"obj":"Sentence"},{"id":"T3","span":{"begin":139,"end":226},"obj":"Sentence"},{"id":"T4","span":{"begin":227,"end":235},"obj":"Sentence"},{"id":"T5","span":{"begin":236,"end":402},"obj":"Sentence"},{"id":"T6","span":{"begin":403,"end":624},"obj":"Sentence"},{"id":"T7","span":{"begin":625,"end":801},"obj":"Sentence"},{"id":"T8","span":{"begin":802,"end":810},"obj":"Sentence"},{"id":"T9","span":{"begin":811,"end":932},"obj":"Sentence"},{"id":"T10","span":{"begin":933,"end":982},"obj":"Sentence"},{"id":"T11","span":{"begin":983,"end":1016},"obj":"Sentence"},{"id":"T12","span":{"begin":1017,"end":1249},"obj":"Sentence"},{"id":"T13","span":{"begin":1250,"end":1362},"obj":"Sentence"},{"id":"T14","span":{"begin":1363,"end":1399},"obj":"Sentence"},{"id":"T15","span":{"begin":1400,"end":1412},"obj":"Sentence"},{"id":"T16","span":{"begin":1413,"end":1572},"obj":"Sentence"},{"id":"T17","span":{"begin":1573,"end":1649},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.\nBACKGROUND: There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19).\nMETHODS: Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes.\nRESULTS: The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]: 8.4-12.8) for AP group and 19.3±2.1 days (95% CI: 15.1-23.5) for the control group. The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. The CT imaging within ten days post-treatment showed no significant differences between the two groups (p\u003e0.05). Both groups had mild adverse events.\nCONCLUSIONS: In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. However, physicians should consider the QT interval changes before using AP."}